Enterovirus 71 encephalitis: A new vaccine on the horizon?

The Lancet

Volumn 381, Issue 9871, 2013, Pages 976-977

  Pallansch, Mark A ^a   Oberste, M Steven ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTEROVIRUS 71 VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS VACCINE;

DISEASE SURVEILLANCE; ENTEROVIRUS 71; ENTEROVIRUS 71 ENCEPHALITIS; EPIDEMIC; HAND FOOT AND MOUTH DISEASE; HUMAN; IMMUNIZATION; MEDICAL DECISION MAKING; NOTE; PRIORITY JOURNAL; VIRUS ENCEPHALITIS;

ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; FEMALE; HUMANS; MALE; VIRAL VACCINES;

EID: 84875382314     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60286-X     Document Type: Note

References (6)

1. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10: 778-90.
2. Chan LG, Parashar UD, Lye MS, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. Clin Infect Dis 2000; 31: 678-83.
3. WHO. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). Geneva, Switzerland: World Health Organization, 2011.
4. Podin Y, Gias EL, Ong F, et al. Sentinel surveillance for human enterovirus 71 in Sarawak, Malaysia: lessons from the first 7 years. BMC Public Health 2006; 6: 180.
5. Lin TY, Twu SJ, Ho MS, Chang LY, Lee CY. Enterovirus 71 o utbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis 2003; 9: 291-93.
6. Zhu F-C, Liang Z-L, Li X-L, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013; 381: 1037-45